Last reviewed · How we verify
ARC-001
At a glance
| Generic name | ARC-001 |
|---|---|
| Sponsor | Arcato Laboratories, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (PHASE1)
- A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (PHASE1)
- A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction (EARLY_PHASE1)
- Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARC-001 CI brief — competitive landscape report
- ARC-001 updates RSS · CI watch RSS
- Arcato Laboratories, Inc. portfolio CI